Comparison of FEV1 change between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Metaregression of treatment duration in days as a predictor of the variation across studies in continence rates.

Liesbeth L. de Wall (14564096)
Antje J. Nieuwhof-Leppink (14564099)
Renske Schappin (279771)

February 2023

Metaregression of treatment duration in days as a predictor of the variation across studies in conti...

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by number of cumulative and number of continuous days of use to define long term use.

Siyana Kurteva (14266086)
Michal Abrahamowicz (129219)
Daniala Weir (14266089)
Tara Gomes (563908)
Robyn Tamblyn (4030964)

December 2022

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by ...

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by subgroup.

Piush J. Mandhane (4164349)
Patricia Paredes Zambrano de Silbernagel (4330060)
Yin Nwe Aung (4330072)
Janie Williamson (4330069)
Bonita E. Lee (363321)
Sheldon Spier (4330063)
Mary Noseworthy (4330075)
William R. Craig (4330066)
David W. Johnson (221347)

August 2017

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by su...

Comparison of hospital length-of-stay between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of hospital length-of-stay between short- (≤7 days) and long- (>7 days) duration regimens...

Comparison of re-exacerbation risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of re-exacerbation risk between short- (≤7 days) and long- (>7 days) duration regimens of...

Comparison of mortality risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of mortality risk between short- (≤7 days) and long- (>7 days) duration regimens of corti...

Comparison of hyperglycemia risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of hyperglycemia risk between short- (≤7 days) and long- (>7 days) duration regimens of c...

Comparison between corticosterone levels on gestational days 11 and 17 in every group.

Zahra Jafari (4236712)
Jogender Mehla (4236724)
Navvab Afrashteh (4236715)
Bryan E. Kolb (4236721)
Majid H. Mohajerani (4236718)

July 2017

Comparison between corticosterone levels on gestational days 11 and 17 in every group.</p

Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration

BRICNOLA C.
DE SIMONE G.
BELLOLI C.
IANNONE P.
BELLUZZI A.
GIONCHETTI P.
CAMPIERI M.
BARBARA L.

January 1994

Background: Steroids are highly effective in active Crohn's disease; clinical relapse following ster...

Reported time-to-onset for short-versus long-term treatments for angioedema and hepatitis, respectively.

Ghazaleh Karimi (433516)
Kristina Star (433517)
G. Niklas Norén (433518)
Staffan Hägg (177360)

July 2013

Drugs with expected long-term treatments (panels B and D) generally presented with longer RTTO th...

Comparison of the HR, HRV parameters, and cortisol between visit 1 and visit 2 in 5-minute segments for a sample participant.

Rui Cao (800989)
Amir M. Rahmani (10090518)
Karen L. Lindsay (8395599)

September 2022

This participant demonstrated an obvious difference in HR, HRV parameters, and cortisol.</p

Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.

Elżbieta Jabłonowska (587025)
Ewa Siwak (6239999)
Monika Bociąga-Jasik (3779029)
Jacek Gąsiorowski (477404)
Anna Kalinowska (6240002)
Ewa Firląg Burkacka (6240005)
Kamila Wójcik-Cichy (6240008)
Anna Piątek (6240011)
Iwona Cielniak (6240014)
Andrzej Horban (4930)

January 2019

Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.</p

Comparison of the treatment side effects among sodium valproate and dexamethasone groups 2 hours post-treatment.

Shahir Mazaheri (707108)
Jalal Poorolajal (295323)
Akram Hosseinzadeh (707109)
Mohammad Mahdi Fazlian (707110)

March 2015

Comparison of the treatment side effects among sodium valproate and dexamethasone groups 2 hours ...

Comparing duration of hospitalization in the intervention and control groups.

Marjaneh Zarkesh (17621683)
Sadroddin Mahdipour (11141342)
Safoora Aghili (17621686)
Atefeh Jafari (9405893)
Seyyedeh Azadeh Hoseini Nouri (17621689)
Afagh Hassanzadeh Rad (11141351)
Maryam Ghalandari (14441781)
Manijeh Tabrizi (17621692)

December 2023

Comparing duration of hospitalization in the intervention and control groups.</p

Comparison of the keff evolution over the first cycle (left) and over the operational period of 40 cycles (right).

Bruno Merk (545638)
Ulrich Rohde (545639)
Varvara Glivici-Cotruţă (545640)
Dzianis Litskevich (545641)
Susanne Scholl (545642)

April 2014

Comparison of the keff evolution over the first cycle (left) and over the operational ...

Metaregression of treatment duration in days as a predictor of the variation across studies in continence rates.

Liesbeth L. de Wall (14564096)
Antje J. Nieuwhof-Leppink (14564099)
Renske Schappin (279771)

February 2023

Metaregression of treatment duration in days as a predictor of the variation across studies in conti...

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by number of cumulative and number of continuous days of use to define long term use.

Siyana Kurteva (14266086)
Michal Abrahamowicz (129219)
Daniala Weir (14266089)
Tara Gomes (563908)
Robyn Tamblyn (4030964)

December 2022

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by ...

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by subgroup.

Piush J. Mandhane (4164349)
Patricia Paredes Zambrano de Silbernagel (4330060)
Yin Nwe Aung (4330072)
Janie Williamson (4330069)
Bonita E. Lee (363321)
Sheldon Spier (4330063)
Mary Noseworthy (4330075)
William R. Craig (4330066)
David W. Johnson (221347)

August 2017

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by su...

Comparison of hospital length-of-stay between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of hospital length-of-stay between short- (≤7 days) and long- (>7 days) duration regimens...

Comparison of re-exacerbation risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of re-exacerbation risk between short- (≤7 days) and long- (>7 days) duration regimens of...

Comparison of mortality risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of mortality risk between short- (≤7 days) and long- (>7 days) duration regimens of corti...

Comparison of hyperglycemia risk between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Zhen Zhao (159931)
Owen Lou (17712023)
Yiyang Wang (291591)
Raymond Yin (16914084)
Carrie Gong (17712026)
Florence Deng (17712029)
Ethan C. Wu (17712032)
Jing Yi Xie (17712035)
Jerry Wu (2997408)
Avery Ma (17712038)
Yongzhi Guo (295416)
Wei Ting Xiong (17712041)

December 2023

Comparison of hyperglycemia risk between short- (≤7 days) and long- (>7 days) duration regimens of c...

Comparison between corticosterone levels on gestational days 11 and 17 in every group.

Zahra Jafari (4236712)
Jogender Mehla (4236724)
Navvab Afrashteh (4236715)
Bryan E. Kolb (4236721)
Majid H. Mohajerani (4236718)

July 2017

Comparison between corticosterone levels on gestational days 11 and 17 in every group.</p

Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration

BRICNOLA C.
DE SIMONE G.
BELLOLI C.
IANNONE P.
BELLUZZI A.
GIONCHETTI P.
CAMPIERI M.
BARBARA L.

January 1994

Background: Steroids are highly effective in active Crohn's disease; clinical relapse following ster...

Reported time-to-onset for short-versus long-term treatments for angioedema and hepatitis, respectively.

Ghazaleh Karimi (433516)
Kristina Star (433517)
G. Niklas Norén (433518)
Staffan Hägg (177360)

July 2013

Drugs with expected long-term treatments (panels B and D) generally presented with longer RTTO th...

Comparison of the HR, HRV parameters, and cortisol between visit 1 and visit 2 in 5-minute segments for a sample participant.

Rui Cao (800989)
Amir M. Rahmani (10090518)
Karen L. Lindsay (8395599)

September 2022

This participant demonstrated an obvious difference in HR, HRV parameters, and cortisol.</p

Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.

Elżbieta Jabłonowska (587025)
Ewa Siwak (6239999)
Monika Bociąga-Jasik (3779029)
Jacek Gąsiorowski (477404)
Anna Kalinowska (6240002)
Ewa Firląg Burkacka (6240005)
Kamila Wójcik-Cichy (6240008)
Anna Piątek (6240011)
Iwona Cielniak (6240014)
Andrzej Horban (4930)

January 2019

Comparison of results before the introduction of DTG/DRV/r therapy and at 48 weeks of treatment.</p

Comparison of the treatment side effects among sodium valproate and dexamethasone groups 2 hours post-treatment.

Shahir Mazaheri (707108)
Jalal Poorolajal (295323)
Akram Hosseinzadeh (707109)
Mohammad Mahdi Fazlian (707110)

March 2015

Comparison of the treatment side effects among sodium valproate and dexamethasone groups 2 hours ...

Comparing duration of hospitalization in the intervention and control groups.

Marjaneh Zarkesh (17621683)
Sadroddin Mahdipour (11141342)
Safoora Aghili (17621686)
Atefeh Jafari (9405893)
Seyyedeh Azadeh Hoseini Nouri (17621689)
Afagh Hassanzadeh Rad (11141351)
Maryam Ghalandari (14441781)
Manijeh Tabrizi (17621692)

December 2023

Comparing duration of hospitalization in the intervention and control groups.</p

Comparison of the keff evolution over the first cycle (left) and over the operational period of 40 cycles (right).

Bruno Merk (545638)
Ulrich Rohde (545639)
Varvara Glivici-Cotruţă (545640)
Dzianis Litskevich (545641)
Susanne Scholl (545642)

April 2014

Comparison of the keff evolution over the first cycle (left) and over the operational ...

Metaregression of treatment duration in days as a predictor of the variation across studies in continence rates.

Liesbeth L. de Wall (14564096)
Antje J. Nieuwhof-Leppink (14564099)
Renske Schappin (279771)

February 2023

Metaregression of treatment duration in days as a predictor of the variation across studies in conti...

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by number of cumulative and number of continuous days of use to define long term use.

Siyana Kurteva (14266086)
Michal Abrahamowicz (129219)
Daniala Weir (14266089)
Tara Gomes (563908)
Robyn Tamblyn (4030964)

December 2022

Comparison of average daily and starting opioid dose between episodic and long-term opioid users by ...

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by subgroup.

Piush J. Mandhane (4164349)
Patricia Paredes Zambrano de Silbernagel (4330060)
Yin Nwe Aung (4330072)
Janie Williamson (4330069)
Bonita E. Lee (363321)
Sheldon Spier (4330063)
Mary Noseworthy (4330075)
William R. Craig (4330066)
David W. Johnson (221347)

August 2017

Average change in duration of symptoms (days) in azithromycin versus control treatment arms by su...

Comparison of FEV<sub>1</sub> change between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Abstract

Extracted data

Comparison of FEV<sub>1</sub> change between short- (≤7 days) and long- (>7 days) duration regimens of corticosteroids.

Abstract

Extracted data

Related items

Related items